In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Opinion|Videos|January 31, 2025 (Updated: January 31, 2025)
Overview of Process of CAR-T Therapy
This segment examines the decision-making process between CAR-T therapy and other innovative treatments, exploring scenarios where alternative therapies may be more appropriate.
Advertisement
Video content above is prompted by the following:
- How do you weigh the choice between CAR-T therapy and other innovative agents?
- Under what circumstances might you consider alternative treatments over CAR-T?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5